Details of Disease

General Information of Disease (ID: DISHT9AE)

Disease Name	Pleural disease
Synonyms	non-neoplastic pleural disease; pleural disorders; pleural disorder; pleura disease or disorder; pleura disease; disorder of pleura; disease or disorder of pleura; disease of pleura
Disease Class	CB27: Pleural effusion
Definition	A non-neoplastic or neoplastic disorder that affects the pleura. Representative examples include pleural infection, pleural mesothelioma, and pleural solitary fibrous tumor.
Disease Hierarchy	DISWD40R: Disease DISFWC2Z: Lower respiratory tract disorder DISHT9AE: Pleural disease
ICD Code	ICD-11 ICD-11: CB27 ICD-10 ICD-10: J94.9 Expand ICD-11 'CB2Z Expand ICD-10 'J94.9
Disease Identifiers	MONDO ID MONDO_0002037 MESH ID D010995 UMLS CUI C0032226 MedGen ID 10804 SNOMED CT ID 88075009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Talc	DMJRPYP	Approved	NA	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GC-1008	DM6R4DO	Phase 1	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCL2	TTNAY0P	Limited	Biomarker	[3]
CXCR3	TT1UCIJ	Limited	Biomarker	[4]
IL4	TTLGTKB	Limited	Biomarker	[4]
MSLN	TT4RXME	Limited	Biomarker	[5]
TNC	TTUCPMY	Limited	Biomarker	[6]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CARD8	OTXXZYWU	Limited	Biomarker	[7]
TIMP2	OT8S1RRP	Limited	Biomarker	[7]
SRSF5	OTC5WP98	Strong	Altered Expression	[8]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3	Asbestos exposure induces MCP-1 secretion by pleural mesothelial cells.Exp Lung Res. 2000 Jun;26(4):241-55. doi: 10.1080/019021400404528.
4	Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.Am J Respir Cell Mol Biol. 2011 Oct;45(4):795-803. doi: 10.1165/rcmb.2010-0435OC. Epub 2011 Feb 25.
5	Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.BMC Cancer. 2017 Mar 23;17(1):212. doi: 10.1186/s12885-017-3209-5.
6	Tenascin expression and distribution in pleural inflammatory and fibrotic diseases.J Histochem Cytochem. 2000 Sep;48(9):1257-68. doi: 10.1177/002215540004800909.
7	Genes involved in innate immunity associated with asbestos-related fibrotic changes.Occup Environ Med. 2014 Jan;71(1):48-54. doi: 10.1136/oemed-2013-101555. Epub 2013 Oct 4.
8	SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer.Lung Cancer. 2016 Sep;99:57-65. doi: 10.1016/j.lungcan.2016.05.018. Epub 2016 May 26.